In KATE2, T-DM1 plus atezolizumab did not show a clinically meaningful improvement in PFS compared to T-DM1 plus placebo in patients with HER2+ advanced breast cancer who have been treated with trastuzumab and a taxane (56). This evidence concerns the gene ERBB2 and breast carcinoma.